COX2 upregulation in BRAFV600E CRC PDX tumors treated with dabrafenib + trametinib for 3 or 21 d was corroborated by IHC (Fig. 5i,j), which parallels what was observed with SRC in these same PDX persists in residual tumors even at late time points. This evidence concerns the gene SRC and colorectal carcinoma.